Gopalsamy A, Aulabaugh AE, Barakat A, Beaumont KC, Cabral S, Canterbury DP, et al. PF-07059013: a noncovalent modulator of hemoglobin for treatment of sickle cell disease. J Med Chem. 2021;64(1):326–42.
Article CAS PubMed Google Scholar
Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14:263–92.
Article CAS PubMed Google Scholar
Ahmed MH, Ghatge MS, Safo MK. Hemoglobin: structure, function and allostery. Subcell Biochem. 2020;94:345–82.
Article CAS PubMed PubMed Central Google Scholar
Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–31.
Article CAS PubMed Google Scholar
Odievre MH, Verger E, Silva-Pinto AC, Elion J. Pathophysiological insights in sickle cell disease. Indian J Med Res. 2011;134(4):532–7.
CAS PubMed PubMed Central Google Scholar
Nita B. Vasaikar SS, Swati Patil, L.B. Borse, S.L. Borse, S.P. Pawar. 2015. A review on sickle cell anemia.
Meier ER. Treatment options for sickle cell disease. Pediatr Clin North Am. 2018;65(3):427–43.
Blair HA. Voxelotor: first approval. Drugs. 2020;80(2):209–15.
Han J, Saraf SL, Gordeuk VR. Systematic review of voxelotor: a first-in-class sickle hemoglobin polymerization inhibitor for management of sickle cell disease. Pharmacotherapy. 2020;40(6):525–34.
Article CAS PubMed Google Scholar
Hoppe C, Neumayr L. Sickle cell disease: monitoring, current treatment, and therapeutics under development. Hematol Oncol Clin North Am. 2019;33(3):355–71.
Study of single and multiple ascending doses of PF-07059013 in healthy adult participants: Clinical Trials.gov; 2022 [Available from: https://clinicaltrials.gov/ct2/show/NCT04323124.
McArthur JG, Svenstrup N, Chen C, Fricot A, Carvalho C, Nguyen J, et al. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2020;105(3):623–31.
Article CAS PubMed PubMed Central Google Scholar
Knee KM, Jasuja R, Barakat A, Rao D, Wenzel Z, Jasti J, et al. PF-07059013: a non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease. Am J Hematol. 2021;96(8):E272–5.
Article CAS PubMed PubMed Central Google Scholar
Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016;175(1):141–53.
Article CAS PubMed Google Scholar
An G. Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds. J Clin Pharmacol. 2020;60(2):149–63.
Article CAS PubMed Google Scholar
Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56(3):248–52.
Article CAS PubMed Google Scholar
Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–32.
Article CAS PubMed Google Scholar
An G, Liu W, Katz DA, Marek GJ, Awni W, Dutta S. Population pharmacokinetics of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens. Biopharm Drug Dispos. 2014;35(7):417–29.
Article CAS PubMed Google Scholar
Wu N, Katz DA, An G. A target-mediated drug disposition model to explain nonlinear pharmacokinetics of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor SPI-62 in healthy adults. J Clin Pharmacol. 2021;61(11):1442–53.
Article CAS PubMed PubMed Central Google Scholar
Wright DH, Stone JA, Crumley TM, Wenning L, Zheng W, Yan K, et al. Pharmacokinetic-pharmacodynamic studies of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects. Br J Clin Pharmacol. 2013;76(6):917–31.
Article CAS PubMed PubMed Central Google Scholar
An G. Small-molecule compounds exhibiting target-mediated drug disposition (TMDD): a minireview. J Clin Pharmacol. 2017;57(2):137–50.
Article CAS PubMed Google Scholar
Bach T, Jiang Y, Zhang X, An G. General pharmacokinetic features of small-molecule compounds exhibiting target-mediated drug disposition (TMDD): a simulation-based study. J Clin Pharmacol. 2019;59(3):394–405.
Article CAS PubMed Google Scholar
O’Donnell BJ, Guo L, Ghosh S, Shah FA, Strollo PJ Jr, McVerry BJ, et al. Sleep phenotype in the Townes mouse model of sickle cell disease. Sleep Breath. 2019;23(1):333–9.
Sauro HM. Enzyme kinetics for systems biology. 2nd ed. Seattle: Ambrosius Publishing; 2012.
Eaton WA, Henry ER, Hofrichter J, Mozzarelli A. Is cooperative oxygen binding by hemoglobin really understood? Nature Structural Biology. 1999;6(4):351–8.
Article CAS PubMed Google Scholar
Leow MK. Configuration of the hemoglobin oxygen dissociation curve demystified: a basic mathematical proof for medical and biological sciences undergraduates. Adv Physiol Educ. 2007;31(2):198–201.
Holt JM, Ackers GK. The Hill coefficient: inadequate resolution of cooperativity in human hemoglobin. Methods Enzymol. 2009;455:193–212.
Article CAS PubMed Google Scholar
Adair GS. 1925 The hemoglobin system. V.I The oxygen dissociation curve of hemoglobin. J Biol Chem. 63(2):529-45.
An G, Lee KSS, Yang J, Hammock BD. Target-mediated drug disposition-a class effect of soluble epoxide hydrolase inhibitors. J Clin Pharmacol. 2021;61(4):531–7.
Article CAS PubMed Google Scholar
van Waterschoot RAB, Parrott NJ, Olivares-Morales A, Lave T, Rowland M, Smith DA. Impact of target interactions on small-molecule drug disposition: an overlooked area. Nat Rev Drug Discov. 2018;17(4):299.
An G, Katz DA. 2022. Importance of target-mediated drug disposition (TMDD) of small-molecule compounds and its impact on drug development - example of the class effect of HSD-1 inhibitors. J Clin Pharmacol. https://doi.org/10.1002/jcph.2185.
Bohr C, Hasselbalch K, Krogh A. About a new biological relation of high importance that the blood carbonic acid tension exercises on its oxygen binding. Skand Arch Physiol. 1904;16:402–12.
Severinghaus JW. Simple, accurate equations for human blood O2 dissociation computations. J Appl Physiol Respir Environ Exerc Physiol. 1979;46(3):599–602.
Hall C, Lueshen E, Mosat A, Linninger AA. Interspecies scaling in pharmacokinetics: a novel whole-body physiologically based modeling framework to discover drug biodistribution mechanisms in vivo. J Pharm Sci. 2012;101(3):1221–41.
Article CAS PubMed Google Scholar
van Beekvelt MCP, Colier WNJM, Wevers RA, van Engelen BGM. Performance of near-infrared spectroscopy in measuring local O-2 consumption and blood flow in skeletal muscle. J Appl Physiol. 2001;90(2):511–9.
Arya R, Rolan PE, Wootton R, Posner J, Bellingham AJ. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Br J Haematol. 1996;93(4):817–21.
留言 (0)